Women seek greater influence in research, prevention policies. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Women seek greater influence in research, prevention policies. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

AIDS Policy Law. 1995 Mar 10;10(4):1, 8-9. Unique Identifier : AIDSLINE AIDS/95700213

Abstract: HIV-positive cases among women are rising at such a rapid rate that by the year 2000, AIDS will be the second greatest killer of women between the ages of 18 and 44, surpassing heart disease and accidents. Womens' needs, however, are being largely ignored in the fight against this disease. Recently, AZT, a drug that was shown to help counter the HIV virus in men, has been shown to cut the risk of perinatal HIV infection by two-thirds in a trial on pregnant women. Some women, however, do not trust the study's findings because they worry that AZT may turn out to be the thalidomide of the 1990s. Until AIDS symptoms were defined as including uniquely female complications, women were left out of access to publicly-funded medical care and government disability benefits. Additionally, health care providers are not doing enough to help newly diagnosed women deal with the problems of domestic violence, abuse, and intimidation. Karen Rothenberg, of the University of Maryland School of Law, states that HIV-positive women are more apt to fear loss of their social structures, such as marriage, partnership or family, than economic complications, such as loss of employment or health insurance.

Keywords: *Acquired Immunodeficiency Syndrome/DRUG THERAPY/EPIDEMIOLOGY/ *PREVENTION & CONTROL Adolescence Adult Contact Tracing Diagnostic Errors *Health Policy Health Services Needs and Demand Human Incidence Physician-Patient Relations *Research Sexual Partners Women's Health Zidovudine/THERAPEUTIC USE NEWSLETTER ARTICLE
950930
M9591280

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .